Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2017

View Archived Issues

Arcus Biosciences completes series C financing, begins two clinical trials

OX1 receptor antagonist C4X_3256 demonstrates efficacy in nicotine dependence rat model

Preclinical results for PF-3628, a new non-catechol D1 receptor agonist for schizophrenia

Clinical progress reported for Pfizer's IRAK-4 inhibitor PF-06650833

CRISPR Therapeutics, Casebia Therapeutics and CureVac form gene-editing program collaboration

EMA committee supports approval of Endoceutics' Intrarosa

FDA approves Allergan's sNDA for Vraylar

European Commission grants marketing authorization for self-injectable formulation of Benlysta

Bayer and Loxo Oncology collaborate to develop and commercialize highly selective TRK inhibitors

Certainty Therapeutics to develop CAR-T technology from Wistar Institute

Dosing begins in first-in-human phase Ib study of DEN-181

EC approves Faslodex in combination with palbociclib for HR+, HER2- breast cancer

EMA's CHMP issues positive opinion on Adcetris for CTCL

Phase II study of topical radezolid for acne begins

FDA approves Fasenra for severe eosinophilic asthma

EMA grants Motrem access to PRIME scheme for septic shock

Discovery of novel orally bioavailable CDK12 covalent inhibitors at Aurigene

Achillion reports preliminary data from phase II study of ACH-4471 in C3G

Boehringer Ingelheim's adalimumab biosimilar, Cyltezo, approved in E.U.

Novel IAP antagonists identified at Medshine Discovery

Everon Biosciences describes compounds to remove senescence-associated macrophages

BeiGene begins pivotal trials for BGB-3111

Astar Biotech divulges novel tyrosine kinase Bcr-Abl inhibitors

Monopar Therapeutics acquires phase II cancer drug candidate

The University of Texas discovers novel sigma1/2 receptor antagonists

New yohimbine analogues synthesized at the University of Florida

First commercial launch for Fotivda

Otsuka offers overview of third quarter 2017

First-in-human results provided for TR-Pharm's anti-interleukin-1 biologic RPH-104

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...